INFORMATION BY CANCER TYPE

Ovarian

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer
BY Ursula Matulonis, M.D.
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
Rucaparib Shows Promising Activity in Recurrent Ovarian Cancer
BY Brielle Urciuoli
Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.
Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer
BY Elizabeth Swisher, M.D.
Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.
After Misdiagnosis, Patient Sees Promise With Immunotherapy Combination for Advanced Ovarian Cancer
BY Allie Casey
Marcia Goglia was given a laxative in the ER for what turned out to be ovarian cancer.
Cancer-Free
BY Nora Mackin Lally
Diagnostic Laparoscopies Can Prevent Future Surgeries in Ovarian Cancer
BY Allie Strickler
Diagnostic laparoscopy can play a role in predicting surgery outcomes for patients with ovarian cancer.
What's the Best Chemotherapy Strategy in Ovarian Cancer?
BY Danielle Bucco
The best chemotherapy strategy (IP versus IV) for patients with ovarian cancer is still being debated. Franco M. Muggia, M.D., weighs in.
A Voice for Patients With Ovarian Cancer
BY Brielle Urciuoli
The Georgia Ovarian Cancer Alliance compiled a book of stories from women who were touched by ovarian cancer. 
Program Opens to Expand Patient Access to Niraparib for Ovarian Cancer
BY Brielle Urciuoli
An expanded access program (EAP) was just opened up for ceratain patients with ovarian cancer to receive niraparib.
Irregular Menstrual Cycles May Offer Insight to Ovarian Cancer Risk
BY Brielle Urciuoli
A recent study examined the relationship between polycystic ovarian syndrome, long or irregular periods and ovarian cancer risk. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Ovarian Epithelial Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial cancer.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment.
Ovarian Germ Cell Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian germ cell tumors.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Ovarian Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing ovarian cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Ovarian Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for ovarian cancer.